{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-269635","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-06-12T20:55:55+00:00","discovered_at":"2026-06-12T20:57:00.287541+00:00","generated_at":"2026-06-12T20:58:56.211620+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants","bullets":["Priced 8,933,334 shares at $37.50/share and 1,733,333 pre-funded warrants at $37.499 each.","Gross proceeds ~$400M; net proceeds ~$376M (or ~$432.4M if underwriters' option fully exercised).","Underwriters granted 30-day option to purchase up to 1,600,000 additional shares.","Offering expected to close June 15, 2026; joint book-runners: Jefferies, Goldman Sachs, Morgan Stanley, Barclays.","Net proceeds for general corporate purposes and pipeline advancement (no specific allocation disclosed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-269635","json":"https://secwatch.observer/filing/0001193125-26-269635.json","markdown":"https://secwatch.observer/filing/0001193125-26-269635.md","text":"https://secwatch.observer/filing/0001193125-26-269635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/0001193125-26-269635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/d152122d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:58:56.211620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd25f2409ef89c97c2f4c1b169e577b55ebd26f1","claim":"Enliven Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. valued at approximately $376.0 million (effective 2026-06-11).","evidence_excerpt":"On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 8,933,334 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $37.50 per share (the “Firm Shares”), and, in lieu of Firm Shares to certain investors, pre-funded warrants to purchase 1,733,333 Shares (the “Pre-Funded Warrants”) at a price to the public of $37.499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.001 exercise price for each such Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/0001193125-26-269635-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc."},{"label":"Value","value":"approximately $376.0 million"},{"label":"Effective","value":"2026-06-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}